Blanchouin-Emeric N, Zenatti M, Defaye G, Aupetit B
Service de Biochimie Médicale, Faculté de Médecine, Pitié-Salpétrière, Paris, France.
J Steroid Biochem. 1988;30(1-6):453-6. doi: 10.1016/0022-4731(88)90141-0.
The action of verapamil, a calcium channel blocker, on the last step of aldosterone biosynthesis (transformation of 18-hydroxycorticosterone into aldosterone) was studied using duck adrenal mitochondria in the absence of regulatory factors. Results show that 10(-5) M verapamil inhibits the transformation of 18-hydroxycorticosterone into aldosterone by 52.8%. Moreover, our findings show that verapamil induces only a slight inhibition of respiratory capacity without action on respiratory control and does not displace 18-hydroxycorticosterone from cytochrome P450 11 beta which catalyses the reaction. Thus, this study does not explain the mechanism of inhibition induced by verapamil on the last step of aldosterone synthesis but it is of interest to note, for clinical use, that this inhibition is not linked to regulatory factors of aldosterone production. Since primary hyperaldosteronisms are characterized by their independence vis-á-vis regulatory factors, administration of verapamil may be particularly interesting for treatment of primary hyperaldosteronisms.
在无调节因子的情况下,利用鸭肾上腺线粒体研究了钙通道阻滞剂维拉帕米对醛固酮生物合成最后一步(18 - 羟皮质酮转化为醛固酮)的作用。结果显示,10(-5) M的维拉帕米可使18 - 羟皮质酮向醛固酮的转化受到52.8%的抑制。此外,我们的研究结果表明,维拉帕米仅对呼吸能力产生轻微抑制,对呼吸控制无作用,且不会从催化该反应的细胞色素P450 11β上置换18 - 羟皮质酮。因此,本研究并未解释维拉帕米对醛固酮合成最后一步的抑制机制,但值得注意的是,从临床应用角度来看,这种抑制与醛固酮产生的调节因子无关。由于原发性醛固酮增多症的特点是其对调节因子具有独立性,维拉帕米的给药对于原发性醛固酮增多症的治疗可能特别有意义。